Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. | Urology;45(2): 275-81, 1995 Feb. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord.

Gonzalez-Barcena, D; Vadillo-Buenfil, M; Cortez-Morales, A; Fuentes-Garcia, M; Cardenas-Cornejo, I; Comaru-Schally, A M; Schally, A V.

Affiliation

Gonzalez-Barcena D; Hospital de Especialidades, Centro Medico La Raza, IMSS, Mexico.

Urology ; 45(2): 275-81, 1995 Feb.

Article in En | MEDLINE | ID: mdl-7531902

Subject(s)

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Paraplegia / Prostatic Neoplasms / Spinal Cord Compression / Spinal Cord Neoplasms / Gonadotropin-Releasing Hormone Limits: Aged / Humans / Male / Middle aged Language: En Journal: Urology Year: 1995 Document type: Article Affiliation country: Country of publication:

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Paraplegia / Prostatic Neoplasms / Spinal Cord Compression / Spinal Cord Neoplasms / Gonadotropin-Releasing Hormone Limits: Aged / Humans / Male / Middle aged Language: En Journal: Urology Year: 1995 Document type: Article Affiliation country: Country of publication: